



## Advances in Cancer Vaccines: From Bench to Bedside

Guest Editors:

**Prof. Dr. Qizhi Cathy Yao**

**Dr. Alok K. Mishra**

**Dr. Sunil K. Malonia**

Deadline for manuscript  
submissions:

**closed (31 July 2024)**

### Message from the Guest Editors

This Special Issue will cover the latest progress in cancer vaccine research and developments. We aim to provide a comprehensive overview of recent developments in cancer vaccines, including novel targets, formulations, and delivery systems. Furthermore, we intend to explore the potential of combination therapies that incorporate cancer vaccines and the identification of biomarkers to guide patient selection and monitoring. Additionally, the Special Issue will cover the research on mRNA-based cancer vaccines, which represent a promising new approach to cancer immunotherapy due to their flexibility and speed of development.

This Special Issue will be of immense interest to researchers, clinicians, and policymakers involved in cancer immunotherapy, and it is hoped that it will make a significant contribution to the field of cancer therapy, and have a positive impact on patient outcomes.

We invite submissions of original research articles, reviews, and perspectives that provide insights into cancer vaccine development, immune correlates of protection, regulatory and ethical considerations, and other relevant topics. We look forward to your contributions and collaboration.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)